Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Sabra Health Care REIT (SBRA)

Sabra Q1 2024 net income $0.11 per share vs. loss a year earlier; guidance reiterated

Positive Impact 3 of 5 earnings Written later

Sabra Health Care REIT reported first quarter 2024 net income of $26.3 million, or $0.11 per diluted share, compared with a net loss of $9.5 million, or $0.04 per share, a year earlier. Total revenues rose to $166.7 million from $161.3 million, and the company reiterated its 2024 earnings guidance.

Key points

  • Q1 2024 normalized FFO was $0.34 per diluted share, up from $0.33 a year earlier; normalized AFFO was $0.35, up from $0.34.
  • Total revenues were $166.7 million, up from $161.3 million; senior housing managed portfolio operating expenses rose to $49.7 million from $43.6 million.
  • 2024 guidance reiterated: normalized FFO of $1.34 to $1.38 per diluted share and normalized AFFO of $1.39 to $1.43, assuming no 2024 acquisitions or dispositions.
  • Board declared a quarterly dividend of $0.30 per share, payable May 31, 2024, to holders of record as of May 20, 2024.

The filing

CompanySabra Health Care REIT (SBRA)
Form8-K, current report
Filed with the SECMay 8, 2024, 4:06 PM ET
Accession number0001492298-24-000013

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 08, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.